Contribution of glucocorticoids and glucocorticoid receptors to the regulation of neurodegenerative processes

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 8, 2013, Pages 1175-1193

  Vyas, Sheela ^a,b,c   Maatouk, Layal ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Glucocorticoid receptors; Glucocorticoids; Hypothalamic pituitary adrenal axis; Neurodegenerative diseases; Stress

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; ARGIPRESSIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 1 RECEPTOR; CORTICOSTEROID; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; FLUOXETINE; GELDANAMYCIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; STAT5 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRIA TERMINALIS; SUPRACHIASMATIC NUCLEUS; SYNAPTIC TRANSMISSION; ANIMAL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEURODEGENERATIVE DISEASES; RECEPTORS, GLUCOCORTICOID; STRESS, PSYCHOLOGICAL;

EID: 84891702178     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: None     Document Type: Article

References (224)

1. Hench, P.S.; Kendall, E.C.; Slocumb, C.H. Polley, H. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin., 1949, 24 (8), 181-197.
2. Reichstein, T. Chemistry of adrenal cortex hormones. Bull. Schweiz Akad. Med. Wiss., 1951, 7 (5-6), 359-370.
3. Hench, P.S.; Kendall, E.C.; Slocumb, C.H.; Polley, H.F. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch. Intern. Med. (Chic.), 1950, 85 (4), 545-666.
4. Kaal, E.C.A.; Vecht, C.J. The management of brain edema in brain tumors. Curr. Opin. Oncol., 2004, 16 (6), 593-600.
5. Roth, P.; Wick, W.; Weller, M. Steroids in neurooncology: actions, indications, side-effects. Curr. Opin. Neurol., 2010, 23 (6), 597-602.
6. Polman, C.H.; Uitdehaag, B.M. Drug treatment of multiple sclerosis. Br. Med. J., 2000, 321 (7259), 490-494.
7. Frohman, E.M.; Racke, M.K.; Raine, C.S. Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med., 2006, 354 (9), 942-955.
8. McFarland, H.F.; Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol., 2007, 8 (9), 913-919.
9. Frisullo, G.; Nociti, V.; Iorio, R.; Katia Patanella, A.; Bianco, A.; Caggiula, M.; Sancricca, C.; Tonali, P.A.; Mirabella, M.; Batocchi, A.P. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin. Immunol., 2007, 124 (3), 284-293.
10. van Winsen, L.M.; Polman, C.H.; Dijkstra, C.D.; Tilders, F.J.; Uitdehaag, B.M. Suppressive effect of glucocorticoids on TNFalpha production is associated with their clinical effect in multiple sclerosis. Mult. Scler., 2010, 16 (4), 500-502.
11. Saidha, S.; Mok, T.H.; Butler, M.; Fanning, N.; Harrington, H. Multiple sclerosis exceptionally presenting as parkinsonism responds to intravenous methylprednisolone. J. Clin. Neurosci., 2010, 17 (5), 654-655.
12. Then Bergh, F.; Kumpfel, T.; Schumann, E.; Held, U.; Schwan, M.; Blazevic, M.; Wismuller, A.; Holsboer, F.; Yassouridis, A.; Uhr, M.; Weber, F.; Daumer, M.; Trenkwalder, C.; Auer, D.P. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis-reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol., 2006, 6, 19.
13. Xu, L.; Xu, Z.; Xu, M. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis. Clin. Exp. Immunol., 2009, 158 (1), 26-30.
14. Whitaker, J.N.; Layton, B.A.; Herman, P.K.; Kachelhofer, R.D.; Burgard, S.; Bartolucci, A.A. Correlation of myelin basic proteinlike material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann. Neurol., 1993, 33 (1), 10-17.
15. Luther, C.; Adamopoulou, E.; Stoeckle, C.; Brucklacher-Waldert, V.; Rosenkranz, D.; Stoltze, L.; Lauer, S.; Poeschel, S.; Melms, A.; Tolosa, E. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J. Immunol., 2009, 183 (2), 841-848.
16. Mazzone, E.; Vasco, G.; Sormani, M.P.; Torrente, Y.; Berardinelli, A.; Messina, S.; D'Amico, A.; Doglio, L.; Politano, L.; Cavallaro, F.; Frosini, S.; Bello, L.; Bonfiglio, S.; Zucchini, E.; De Sanctis, R.; Scutifero, M.; Bianco, F.; Rossi, F.; Motta, M.C.; Sacco, A.; Donati, M.A.; Mongini, T.; Pini, A.; Battini, R.; Pegoraro, E.; Pane, M.; Gasperini, S.; Previtali, S.; Napolitano, S.; Martinelli, D.; Bruno, C.; Vita, G.; Comi, G.; Bertini, E.; Mercuri, E. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology, 2011, 77 (3), 250-256.
17. Nagane, Y.; Suzuki, S.; Suzuki, N.; Utsugisawa, K. Early aggressive treatment strategy against myasthenia gravis. Eur. Neurol., 2011, 65 (1), 16-22.
18. Bae, J.S.; Go, S.M.; Kim, B.J. Clinical predictors of steroidinduced exacerbation in myasthenia gravis. J. Clin. Neurosci., 2006, 13 (10), 1006-1010.
19. Sathasivam, S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat. Clin. Prac. Neurol., 2008, 4 (6), 317-327.
20. Wolkowitz, O.M. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology, 1994, 19 (3), 233-255.
21. Starkman, M.N.; Giordani, B.; Berent, S.; Schork, M.A.; Schteingart, D.E. Elevated cortisol levels in Cushing's disease are associated with cognitive decrements. Psychosom. Med., 2001, 63 (6), 985-993.
22. Shah, S.K.; Gecys, G.T. Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect. J. Am. Osteopath. Assoc., 2006, 106 (11), 653-657.
23. Chrousos, G.P.; Kino, T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann. NY Acad. Sci., 2009, 1179, 153-166.
24. Ahlbom, E.; Gogvadze, V.; Chen, M.; Celsi, G.; Ceccatelli, S. Prenatal exposure to high levels of glucocorticoids increases the susceptibility of cerebellar granule cells to oxidative stress-induced cell death. Proc. Natl. Acad. Sci. USA, 2000, 97 (26), 14726-14730.
25. Tam, E.W.; Chau, V.; Ferriero, D.M.; Barkovich, A.J.; Poskitt, K.J.; Studholme, C.; Fok, E.D.; Grunau, R.E.; Glidden, D.V.; Miller, S.P. Preterm cerebellar growth impairment after postnatal exposure to glucocorticoids. Sci. Transl. Med., 2011, 3 (105), 105ra105.
26. de Kloet, E.R.; Reul, J.M.; Sutanto, W. Corticosteroids and the brain. J. Steroid Biochem. Mol. Biol., 1990, 37 (3), 387-394.
27. Rosenfeld, P.; van Eekelen, J.A.; Levine, S.; de Kloet, E.R. Ontogeny of corticosteroid receptors in the brain. Cell Mol. Neurobiol., 1993, 13 (4), 295-319.
28. De Kloet, E.R.; Vreugdenhil, E.; Oitzl, M.S.; Joels, M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 1998, 19 (3), 269-301.
29. Ahima, R.; Krozowski, Z.; Harlan, R. Type I corticosteroid receptor-like immunoreactivity in the rat CNS: distribution and regulation by corticosteroids. J. Comp. Neurol., 1991, 313 (3), 522-538.
30. Fuxe, K.; Wikstrom, A.C.; Okret, S.; Agnati, L.F.; Harfstrand, A.; Yu, Z.Y.; Granholm, L.; Zoli, M.; Vale, W.; Gustafsson, J.A. Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel-and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinology, 1985, 117 (5), 1803-1812.
31. Aronsson, M.; Fuxe, K.; Dong, Y.; Agnati, L.F.; Okret, S.; Gustafsson, J.A. Localization of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proc. Natl. Acad. Sci. USA, 1988, 85 (23), 9331-9335.
32. Ahima, R.S.; Harlan, R.E. Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience, 1990, 39 (3), 579-604.
33. Cintra, A.; Zoli, M.; Rosen, L.; Agnati, L.F.; Okret, S.; Wikstrom, A.C.; Gustaffsson, J.A.; Fuxe, K. Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. Neuroscience, 1994, 62 (3), 843-897.
34. van Steensel, B.; van Binnendijk, E.P.; Hornsby, C.D.; van der Voort, H.T.; Krozowski, Z.S.; de Kloet, E.R.; van Driel, R. Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. J. Cell Sci., 1996, 109 (Pt 4), 787-792.
35. Han, F.; Ozawa, H.; Matsuda, K.; Nishi, M.; Kawata, M. Colocalization of mineralocorticoid receptor and glucocorticoid receptor in the hippocampus and hypothalamus. Neurosci. Res., 2005, 51 (4), 371-381.
36. Piazza, P.V.; Le Moal, M. Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res. Brain Res. Rev., 1997, 25 (3), 359-372.
37. Tronche, F.; Kellendonk, C.; Kretz, O.; Gass, P.; Anlag, K.; Orban, P.C.; Bock, R.; Klein, R.; Schutz, G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet., 1999, 23 (1), 99-103.
38. Barrot, M.; Marinelli, M.; Abrous, D.N.; Rouge-Pont, F.; Le Moal, M.; Piazza, P.V. The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent. Eur. J. Neurosci., 2000, 12 (3), 973-979.
39. Berger, S.; Wolfer, D.P.; Selbach, O.; Alter, H.; Erdmann, G.; Reichardt, H.M.; Chepkova, A.N.; Welzl, H.; Haas, H.L.; Lipp, H.P.; Schutz, G. Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc. Natl. Acad. Sci. USA, 2006, 103 (1), 195-200.
40. McEwen, B.S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev., 2007, 87 (3), 873-904.
41. McEwen, B.S. Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur. J. Pharmacol., 2008, 583 (2-3), 174-185.
42. Akil, H. Stressed and depressed. Nat. Med., 2005, 11 (2), 116-118.
43. Rozeboom, A.M.; Akil, H.; Seasholtz, A.F. Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc. Natl. Acad. Sci. USA, 2007, 104 (11), 4688-4693.
44. Wei, Q.; Hebda-Bauer, E.K.; Pletsch, A.; Luo, J.; Hoversten, M.T.; Osetek, A.J.; Evans, S.J.; Watson, S.J.; Seasholtz, A.F.; Akil, H. Overexpressing the glucocorticoid receptor in forebrain causes an aging-like neuroendocrine phenotype and mild cognitive dysfunction. J. Neurosci., 2007, 27 (33), 8836-8844.
45. Pariante, C.M.; Lightman, S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci., 2008, 31 (9), 464-468.
46. Ambroggi, F.; Turiault, M.; Milet, A.; Deroche-Gamonet, V.; Parnaudeau, S.; Balado, E.; Barik, J.; van der Veen, R.; Maroteaux, G.; Lemberger, T.; Schutz, G.; Lazar, M.; Marinelli, M.; Piazza, P.V.; Tronche, F. Stress and addiction: glucocorticoid receptor in dopaminoceptive neurons facilitates cocaine seeking. Nat. Neurosci., 2009, 12 (3), 247-249.
47. Joels, M.; Baram, T.Z. The neuro-symphony of stress. Nat. Rev. Neurosci., 2009, 10 (6), 459-466.
48. Barik, J.; Parnaudeau, S.; Saint Amaux, A.L.; Guiard, B.P.; Golib Dzib, J.F.; Bocquet, O.; Bailly, A.; Benecke, A.; Tronche, F. Glucocorticoid receptors in dopaminoceptive neurons, key for cocaine, are dispensable for molecular and behavioral morphine responses. Biol. Psychiatry, 2010, 68 (3), 231-239.
49. Cima, I.; Corazza, N.; Dick, B.; Fuhrer, A.; Herren, S.; Jakob, S.; Ayuni, E.; Mueller, C.; Brunner, T. Intestinal epithelial cells synthesize glucocorticoids and regulate T cell activation. J. Exp. Med., 2004, 200 (12), 1635-1646.
50. Weitzman, E.D.; Fukushima, D.; Nogeire, C.; Roffwarg, H.; Gallagher, T.F.; Hellman, L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J. Clin. Endocrinol. Metab., 1971, 33 (1), 14-22.
51. Dallman, M.F.; Engeland, W.C.; Rose, J.C.; Wilkinson, C.W.; Shinsako, J.; Siedenburg, F. Nycthemeral rhythm in adrenal responsiveness to ACTH. Am. J. Physiol., 1978, 235 (5), R210-R218.
52. Hellman, L.; Nakada, F.; Curti, J.; Weitzman, E.D.; Kream, J.; Roffwarg, H.; Ellman, S.; Fukushima, D.K.; Gallagher, T.F. Cortisol is secreted episodically by normal man. J. Clin. Endocrinol. Metab., 1970, 30 (4), 411-422.
53. Veldhuis, J.D.; Iranmanesh, A.; Lizarralde, G.; Johnson, M.L. Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am. J. Physiol., 1989, 257 (1 Pt 1), E6-E14.
54. Windle, R.J.; Wood, S.A.; Shanks, N.; Lightman, S.L.; Ingram, C.D. Ultradian rhythm of basal corticosterone release in the female rat: dynamic interaction with the response to acute stress. Endocrinology, 1998, 139 (2), 443-450.
55. Young, E.A.; Abelson, J.; Lightman, S.L. Cortisol pulsatility and its role in stress regulation and health. Front. Neuroendocrinol., 2004, 25 (2), 69-76.
56. Lightman, S.L.; Wiles, C.C.; Atkinson, H.C.; Henley, D.E.; Russell, G.M.; Leendertz, J.A.; McKenna, M.A.; Spiga, F.; Wood, S.A.; Conway-Campbell, B.L. The significance of glucocorticoid pulsatility. Eur. J. Pharmacol., 2008, 583 (2-3), 255-262.
57. de Kloet, E.R.; Sarabdjitsingh, R.A. Everything has rhythm: focus on glucocorticoid pulsatility. Endocrinology, 2008, 149 (7), 3241-3243.
58. Reppert, S.M.; Weaver, D.R. Coordination of circadian timing in mammals. Nature, 2002, 418 (6901), 935-941.
59. Buijs, R.M.; Wortel, J.; Van Heerikhuize, J.J.; Feenstra, M.G.; Ter Horst, G.J.; Romijn, H.J.; Kalsbeek, A. Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. Eur. J. Neurosci., 1999, 11 (5), 1535-1544.
60. Buijs, R.M.; van Eden, C.G.; Goncharuk, V.D.; Kalsbeek, A. The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J. Endocrinol., 2003, 177 (1), 17-26.
61. Engeland, W.C.; Arnhold, M.M. Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine, 2005, 28 (3), 325-332.
62. Kalsbeek, A.; Palm, I.F.; La Fleur, S.E.; Scheer, F.A.; Perreau-Lenz, S.; Ruiter, M.; Kreier, F.; Cailotto, C.; Buijs, R.M. SCN outputs and the hypothalamic balance of life. J. Biol. Rhythms, 2006, 21 (6), 458-469.
63. Dickmeis, T. Glucocorticoids and the circadian clock. J. Endocrinol., 2009, 200 (1), 3-22.
64. Dallmann, R.; Touma, C.; Palme, R.; Albrecht, U.; Steinlechner, S. Impaired daily glucocorticoid rhythm in Per1 (Brd) mice. J. Comp. Physiol. A. Neuroethol. Sens. Neural Behav. Physiol., 2006, 192 (7), 769-775.
65. Yang, S.; Liu, A.; Weidenhammer, A.; Cooksey, R.C.; McClain, D.; Kim, M.K.; Aguilera, G.; Abel, E.D.; Chung, J.H. The role of mPer2 clock gene in glucocorticoid and feeding rhythms. Endocrinology, 2009, 150 (5), 2153-2160.
66. Kino, T.; Chrousos, G.P. Circadian CLOCK-mediated regulation of target-tissue sensitivity to glucocorticoids: implications for cardiometabolic diseases. Endocr. Dev., 2011, 20, 116-126.
67. Oster, H.; Damerow, S.; Kiessling, S.; Jakubcakova, V.; Abraham, D.; Tian, J.; Hoffmann, M.W.; Eichele, G. The circadian rhythm of glucocorticoids is regulated by a gating mechanism residing in the adrenal cortical clock. Cell Metab., 2006, 4 (2), 163-173.
68. Walker, J.J.; Terry, J.R.; Lightman, S.L. Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. Proc. Biol. Sci., 2010, 277 (1688), 1627-1633.
69. Rankin, J.; Walker, J.J.; Windle, R.; Lightman, S.L.; Terry, J.R. Characterizing dynamic interactions between ultradian glucocorticoid rhythmicity and acute stress using the phase response curve. PLoS One, 2012, 7 (2), e30978.
70. Cullinan, W.E.; Herman, J.P.; Watson, S.J. Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis. J. Comp. Neurol., 1993, 332 (1), 1-20.
71. Herman, J.P.; Cullinan, W.E.; Ziegler, D.R.; Tasker, J.G. Role of the paraventricular nucleus microenvironment in stress integration. Eur. J. Neurosci., 2002, 16 (3), 381-385.
72. Herman, J.P.; Tasker, J.G.; Ziegler, D.R.; Cullinan, W.E. Local circuit regulation of paraventricular nucleus stress integration: glutamate-GABA connections. Pharmacol. Biochem. Behav., 2002, 71 (3), 457-468.
73. Herman, J.P.; Mueller, N.K. Role of the ventral subiculum in stress integration. Behav. Brain Res., 2006, 174 (2), 215-224.
74. Prewitt, C.M.; Herman, J.P. Anatomical interactions between the central amygdaloid nucleus and the hypothalamic paraventricular nucleus of the rat: a dual tract-tracing analysis. J. Chem. Neuroanat., 1998, 15 (3), 173-185.
75. Jankord, R.; Herman, J.P. Limbic regulation of hypothalamopituitary-adrenocortical function during acute and chronic stress. Ann. NY Acad. Sci., 2008, 1148, 64-73.
76. Itoi, K.; Horiba, N.; Tozawa, F.; Sakai, Y.; Sakai, K.; Abe, K.; Demura, H.; Suda, T. Major role of 3', 5'-cyclic adenosine monophosphate-dependent protein kinase A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. Endocrinology, 1996, 137 (6), 2389-2396.
77. Kageyama, K.; Suda, T. Regulatory mechanisms underlying corticotropin-releasing factor gene expression in the hypothalamus. Endocr. J., 2009, 56 (3), 335-344.
78. Karst, H.; Berger, S.; Turiault, M.; Tronche, F.; Schutz, G.; Joels, M. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc. Natl. Acad. Sci. USA, 2005, 102 (52), 19204-19207.
79. Groeneweg, F.L.; Karst, H.; de Kloet, E.R.; Joels, M. Rapid nongenomic effects of corticosteroids and their role in the central stress response. J. Endocrinol., 2011, 209 (2), 153-167.
80. Tasker, J.G.; Di, S.; Malcher-Lopes, R. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology, 2006, 147 (12), 5549-5556.
81. Evanson, N.K.; Tasker, J.G.; Hill, M.N.; Hillard, C.J.; Herman, J.P. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology, 2010, 151 (10), 4811-4819.
82. Russell, G.M.; Henley, D.E.; Leendertz, J.; Douthwaite, J.A.; Wood, S.A.; Stevens, A.; Woltersdorf, W.W.; Peeters, B.W.; Ruigt, G.S.; White, A.; Veldhuis, J.D.; Lightman, S.L. Rapid glucocorticoid receptor-mediated inhibition of hypothalamicpituitary-adrenal ultradian activity in healthy males. J. Neurosci., 2010, 30 (17), 6106-6115.
83. Navarra, P.; Tsagarakis, S.; Faria, M.S.; Rees, L.H.; Besser, G.M.; Grossman, A.B. Interleukins-1 and-6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology, 1991, 128 (1), 37-44.
84. Ericsson, A.; Kovacs, K.J.; Sawchenko, P.E. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J. Neurosci., 1994, 14 (2), 897-913.
85. Vallieres, L.; Rivest, S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology, 1999, 140 (9), 3890-3903.
86. Turnbull, A.V.; Smith, G.W.; Lee, S.; Vale, W.W.; Lee, K.F.; Rivier, C. CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology, 1999, 140 (2), 1013-1017.
87. Serrats, J.; Schiltz, J.C.; Garcia-Bueno, B.; van Rooijen, N.; Reyes, T.M.; Sawchenko, P.E. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron, 2010, 65 (1), 94-106.
88. Schiltz, J.C.; Sawchenko, P.E. Specificity and generality of the involvement of catecholaminergic afferents in hypothalamic responses to immune insults. J. Comp. Neurol., 2007, 502 (3), 455-467.
89. Bethin, K.E.; Vogt, S.K.; Muglia, L.J. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc. Natl. Acad. Sci. USA, 2000, 97 (16), 9317-9322.
90. Zacharowski, K.; Zacharowski, P.A.; Koch, A.; Baban, A.; Tran, N.; Berkels, R.; Papewalis, C.; Schulze-Osthoff, K.; Knuefermann, P.; Zahringer, U.; Schumann, R.R.; Rettori, V.; McCann, S.M.; Bornstein, S.R. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc. Natl. Acad. Sci. USA, 2006, 103 (16), 6392-6397.
91. Tran, N.; Koch, A.; Berkels, R.; Boehm, O.; Zacharowski, P.A.; Baumgarten, G.; Knuefermann, P.; Schott, M.; Kanczkowski, W.; Bornstein, S.R.; Lightman, S.L.; Zacharowski, K. Toll-like receptor 9 expression in murine and human adrenal glands and possible implications during inflammation. J. Clin. Endocrinol. Metab., 2007, 92 (7), 2773-2783.
92. Sarabdjitsingh, R.A.; Joels, M.; de Kloet, E.R. Glucocorticoid pulsatility and rapid corticosteroid actions in the central stress response. Physiol. Behav., 2011, 106 (1), 73-80.
93. Droste, S.K.; de Groote, L.; Atkinson, H.C.; Lightman, S.L.; Reul, J.M.; Linthorst, A.C. Corticosterone levels in the brain show a distinct ultradian rhythm but a delayed response to forced swim stress. Endocrinology, 2008, 149 (7), 3244-3253.
94. Sarabdjitsingh, R.A.; Conway-Campbell, B.L.; Leggett, J.D.; Waite, E.J.; Meijer, O.C.; de Kloet, E.R.; Lightman, S.L. Stress responsiveness varies over the ultradian glucocorticoid cycle in a brain-region-specific manner. Endocrinology, 2010, 151 (11), 5369-5379.
95. Sarabdjitsingh, R.A.; Isenia, S.; Polman, A.; Mijalkovic, J.; Lachize, S.; Datson, N.; de Kloet, E.R.; Meijer, O.C. Disrupted corticosterone pulsatile patterns attenuate responsiveness to glucocorticoid signaling in rat brain. Endocrinology, 2010, 151 (3), 1177-1186.
96. Evans, R.M.; Arriza, J.L. A molecular framework for the actions of glucocorticoid hormones in the nervous system. Neuron, 1989, 2 (2), 1105-1112.
97. Robinson-Rechavi, M.; Escriva Garcia, H.; Laudet, V. The nuclear receptor superfamily. J. Cell Sci., 2003, 116 (Pt 4), 585-586.
98. Glass, C.K.; Saijo, K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol., 2010, 10 (5), 365-376.
99. Grad, I.; Picard, D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell Endocrinol., 2007, 275 (1-2), 2-12.
100. Banerjee, A.; Periyasamy, S.; Wolf, I.M.; Hinds, T.D. Jr.; Yong, W.; Shou, W.; Sanchez, E.R. Control of glucocorticoid and progesterone receptor subcellular localization by the ligand-binding domain is mediated by distinct interactions with tetratricopeptide repeat proteins. Biochemistry, 2008, 47 (39), 10471-10480.
101. Echeverria, P.C.; Mazaira, G.; Erlejman, A.; Gomez-Sanchez, C.; Piwien Pilipuk, G.; Galigniana, M.D. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol. Cell Biol., 2009, 29 (17), 4788-4797.
102. Black, B.E.; Holaska, J.M.; Rastinejad, F.; Paschal, B.M. DNA binding domains in diverse nuclear receptors function as nuclear export signals. Curr. Biol., 2001, 11 (22), 1749-1758.
103. Galigniana, M.D.; Radanyi, C.; Renoir, J.M.; Housley, P.R.; Pratt, W.B. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J. Biol. Chem., 2001, 276 (18), 14884-14889.
104. Wochnik, G.M.; Ruegg, J.; Abel, G.A.; Schmidt, U.; Holsboer, F.; Rein, T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem., 2005, 280 (6), 4609-4616.
105. Elbi, C.; Walker, D.A.; Romero, G.; Sullivan, W.P.; Toft, D.O.; Hager, G.L.; DeFranco, D.B. Molecular chaperones function as steroid receptor nuclear mobility factors. Proc. Natl. Acad. Sci. USA, 2004, 101 (9), 2876-2881.
106. Stavreva, D.A.; Wiench, M.; John, S.; Conway-Campbell, B.L.; McKenna, M.A.; Pooley, J.R.; Johnson, T.A.; Voss, T.C.; Lightman, S.L.; Hager, G.L. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat. Cell Biol., 2009, 11 (9), 1093-1102.
107. Wang, Z.; Chen, W.; Kono, E.; Dang, T.; Garabedian, M.J. Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. Mol. Endocrinol., 2007, 21 (3), 625-634.
108. Nagy, L.; Schwabe, J.W. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci., 2004, 29 (6), 317-324.
109. Xu, W.; Chen, H.; Du, K.; Asahara, H.; Tini, M.; Emerson, B.M.; Montminy, M.; Evans, R.M. A transcriptional switch mediated by cofactor methylation. Science, 2001, 294 (5551), 2507-2511.
110. Rosenfeld, M.G.; Glass, C.K. Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem., 2001, 276 (40), 36865-36868.
111. Garcia-Bassets, I.; Kwon, Y.S.; Telese, F.; Prefontaine, G.G.; Hutt, K.R.; Cheng, C.S.; Ju, B.G.; Ohgi, K.A.; Wang, J.; Escoubet-Lozach, L.; Rose, D.W.; Glass, C.K.; Fu, X.D.; Rosenfeld, M.G. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell, 2007, 128 (3), 505-518.
112. Lonard, D.M.; O'Malley, B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell, 2007, 27 (5), 691-700.
113. Dostert, A.; Heinzel, T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr. Pharm. Des., 2004, 10 (23), 2807-2816.
114. Surjit, M.; Ganti, K.P.; Mukherji, A.; Ye, T.; Hua, G.; Metzger, D.; Li, M.; Chambon, P. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell, 2011, 145 (2), 224-241.
115. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev., 2003, 24 (4), 488-522.
116. Ogawa, S.; Lozach, J.; Benner, C.; Pascual, G.; Tangirala, R.K.; Westin, S.; Hoffmann, A.; Subramaniam, S.; David, M.; Rosenfeld, M.G.; Glass, C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell, 2005, 122 (5), 707-721.
117. McKenna, N.J.; DeFranco, D.B. Molecular endocrinology: A portal for enhanced access and utility of the nuclear receptor signaling atlas (NURSA) web resource. Mol. Endocrinol., 2009, 23 (6), 739.
118. McKenna, N.J.; Cooney, A.J.; DeMayo, F.J.; Downes, M.; Glass, C.K.; Lanz, R.B.; Lazar, M.A.; Mangelsdorf, D.J.; Moore, D.D.; Qin, J.; Steffen, D.L.; Tsai, M.J.; Tsai, S.Y.; Yu, R.; Margolis, R.N.; Evans, R.M.; O'Malley, B.W. Minireview: Evolution of NURSA, the Nuclear Receptor Signaling Atlas. Mol. Endocrinol., 2009, 23 (6), 740-746.
119. Deuschle, M.; Gotthardt, U.; Schweiger, U.; Weber, B.; Korner, A.; Schmider, J.; Standhardt, H.; Lammers, C.H.; Heuser, I. With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. Life Sci., 1997, 61 (22), 2239-2246.
120. Vonsattel, J.P.; Myers, R.H.; Stevens, T.J.; Ferrante, R.J.; Bird, E.D.; Richardson, E.P. Jr. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 1985, 44 (6), 559-577.
121. Petersen, A.; Bjorkqvist, M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci., 2006, 24 (4), 961-967.
122. Heuser, I.J.; Chase, T.N.; Mouradian, M.M. The limbichypothalamic-pituitary-adrenal axis in Huntington's disease. Biol. Psychiatry, 1991, 30 (9), 943-952.
123. Leblhuber, F.; Peichl, M.; Neubauer, C.; Reisecker, F.; Steinparz, F.X.; Windhager, E.; Maschek, W. Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. J. Neurol. Sci., 1995, 132 (1), 76-79.
124. Aziz, N.A.; Pijl, H.; Frolich, M.; van der Graaf, A.W.; Roelfsema, F.; Roos, R.A. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab., 2009, 94 (4), 1223-1228.
125. Bjorkqvist, M.; Petersen, A.; Bacos, K.; Isaacs, J.; Norlen, P.; Gil, J.; Popovic, N.; Sundler, F.; Bates, G.P.; Tabrizi, S.J.; Brundin, P.; Mulder, H. Progressive alterations in the hypothalamic-pituitaryadrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 2006, 15 (10), 1713-1721.
126. Duyckaerts, C.; Delatour, B.; Potier, M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol., 2009, 118 (1), 5-36.
127. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov., 2011, 10 (9), 698-712.
128. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet, 2011, 377 (9770), 1019-1031.
129. Ittner, L.M.; Gotz, J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci., 2011, 12 (2), 65-72.
130. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; Paul, S.M.; Zlokovic, B.V.; Piwnica-Worms, D.; Holtzman, D.M. Pglycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest., 2005, 115 (11), 3285-3290.
131. Gomez-Isla, T.; Hollister, R.; West, H.; Mui, S.; Growdon, J.H.; Petersen, R.C.; Parisi, J.E.; Hyman, B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 1997, 41 (1), 17-24.
132. de Souza, L.C.; Chupin, M.; Lamari, F.; Jardel, C.; Leclercq, D.; Colliot, O.; Lehericy, S.; Dubois, B.; Sarazin, M. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol. Aging, 2012, 33 (7), 1253-1257.
133. Greenwald, B.S.; Mathe, A.A.; Mohs, R.C.; Levy, M.I.; Johns, C.A.; Davis, K.L. Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms. Am. J. Psychiatry, 1986, 143 (4), 442-446.
134. Hatzinger, M.; Z'Brun, A.; Hemmeter, U.; Seifritz, E.; Baumann, F.; Holsboer-Trachsler, E.; Heuser, I.J. Hypothalamic-pituitaryadrenal system function in patients with Alzheimer's disease. Neurobiol. Aging, 1995, 16 (2), 205-209.
135. Rasmuson, S.; Andrew, R.; Nasman, B.; Seckl, J.R.; Walker, B.R.; Olsson, T. Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease. Biol. Psychiatry, 2001, 49 (6), 547-552.
136. Peskind, E.R.; Wilkinson, C.W.; Petrie, E.C.; Schellenberg, G.D.; Raskind, M.A. Increased CSF cortisol in AD is a function of APOE genotype. Neurology, 2001, 56 (8), 1094-1098.
137. Hoogendijk, W.J.; Meynen, G.; Endert, E.; Hofman, M.A.; Swaab, D.F. Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. Neurobiol. Aging, 2006, 27 (5), 780 e1-780 e2.
138. Csernansky, J.G.; Dong, H.; Fagan, A.M.; Wang, L.; Xiong, C.; Holtzman, D.M.; Morris, J.C. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry, 2006, 163 (12), 2164-2169.
139. Elgh, E.; Lindqvist Astot, A.; Fagerlund, M.; Eriksson, S.; Olsson, T.; Nasman, B. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol. Psychiatry, 2006, 59 (2), 155-161.
140. Hartmann, A.; Veldhuis, J.D.; Deuschle, M.; Standhardt, H.; Heuser, I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging, 1997, 18 (3), 285-289.
141. Simard, M.; Hudon, C.; van Reekum, R. Psychological distress and risk for dementia. Curr. Psychiatry Rep., 2009, 11 (1), 41-47.
142. Mejia, S.; Giraldo, M.; Pineda, D.; Ardila, A.; Lopera, F. Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int. Psychogeriatr., 2003, 15 (4), 337-349.
143. Rothman, S.M.; Mattson, M.P. Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromolecular Med., 2010, 12 (1), 56-70.
144. Newcomer, J.W.; Craft, S.; Hershey, T.; Askins, K.; Bardgett, M.E. Glucocorticoid-induced impairment in declarative memory performance in adult humans. J. Neurosci., 1994, 14 (4), 2047-253.
145. Lupien, S.J.; de Leon, M.; de Santi, S.; Convit, A.; Tarshish, C.; Nair, N.P.; Thakur, M.; McEwen, B.S.; Hauger, R.L.; Meaney, M.J. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat. Neurosci., 1998, 1 (1), 69-73.
146. Hardingham, G.E.; Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci., 2010, 11 (10), 682-696.
147. de Kloet, E.R.; Oitzl, M.S.; Joels, M. Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci., 1999, 22 (10), 422-426.
148. Roozendaal, B. Stress and memory: opposing effects of glucocorticoids on memory consolidation and memory retrieval. Neurobiol. Learn. Mem., 2002, 78 (3), 578-595.
149. Smeets, T.; Wolf, O.T.; Giesbrecht, T.; Sijstermans, K.; Telgen, S.; Joels, M. Stress selectively and lastingly promotes learning of context-related high arousing information. Psychoneuroendocrinology, 2009, 34 (8), 1152-1161.
150. Sandi, C. Glucocorticoids act on glutamatergic pathways to affect memory processes. Trends Neurosci., 2011, 34 (4), 165-176.
151. Groc, L.; Choquet, D.; Chaouloff, F. The stress hormone corticosterone conditions AMPAR surface trafficking and synaptic potentiation. Nat. Neurosci., 2008, 11 (8), 868-870.
152. Martin, S.; Henley, J.M.; Holman, D.; Zhou, M.; Wiegert, O.; van Spronsen, M.; Joels, M.; Hoogenraad, C.C.; Krugers, H.J. Corticosterone alters AMPAR mobility and facilitates bidirectional synaptic plasticity. PLoS One, 2009, 4 (3), e4714.
153. Revest, J.M.; Kaouane, N.; Mondin, M.; Le Roux, A.; Rouge-Pont, F.; Vallee, M.; Barik, J.; Tronche, F.; Desmedt, A.; Piazza, P.V. The enhancement of stress-related memory by glucocorticoids depends on synapsin-Ia/Ib. Mol. Psychiatry, 2010, 15 (12), 1125, 1140-1151.
154. de Pablos, R.M.; Villaran, R.F.; Arguelles, S.; Herrera, A.J.; Venero, J.L.; Ayala, A.; Cano, J.; Machado, A. Stress increases vulnerability to inflammation in the rat prefrontal cortex. J. Neurosci., 2006, 26 (21), 5709-5719.
155. Xiao, L.; Feng, C.Z.; Chen, Y.Z. Glucocorticoid Rapidly Enhances NMDA-Evoked Neurotoxicity by Attenuating the NR2AContaining NMDA Receptor-Mediated ERK1/2 Activation. Mol. Endocrinol., 2010, 24 (3), 497-510.
156. Fitzsimons, C.P.; van Hooijdonk, L.W.; Schouten, M.; Zalachoras, I.; Brinks, V.; Zheng, T.; Schouten, T.G.; Saaltink, D.J.; Dijkmans, T.; Steindler, D.A.; Verhaagen, J.; Verbeek, F.J.; Lucassen, P.J.; de Kloet, E.R.; Meijer, O.C.; Karst, H.; Joels, M.; Oitzl, M.S.; Vreugdenhil, E. Knockdown of the glucocorticoid receptor alters functional integration of newborn neurons in the adult hippocampus and impairs fear-motivated behavior. Mol. Psychiatry, 2013, 18 (9), 1005.
157. Gould, E.; Tanapat, P.; McEwen, B.S.; Flugge, G.; Fuchs, E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc. Natl. Acad. Sci. USA, 1998, 95 (6), 3168-3171.
158. Mu, Y.; Gage, F.H. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegener., 2011, 6, 85.
159. Schloesser, R.J.; Manji, H.K.; Martinowich, K. Suppression of adult neurogenesis leads to an increased hypothalamo-pituitaryadrenal axis response. Neuroreport, 2009, 20 (6), 553-557.
160. Surget, A.; Tanti, A.; Leonardo, E.D.; Laugeray, A.; Rainer, Q.; Touma, C.; Palme, R.; Griebel, G.; Ibarguen-Vargas, Y.; Hen, R.; Belzung, C. Antidepressants recruit new neurons to improve stress response regulation. Mol. Psychiatry, 2011, 16 (12), 1177-1188.
161. Stein-Behrens, B.; Mattson, M.P.; Chang, I.; Yeh, M.; Sapolsky, R. Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J. Neurosci., 1994, 14 (9), 5373-5380.
162. Jeong, Y.H.; Park, C.H.; Yoo, J.; Shin, K.Y.; Ahn, S.M.; Kim, H.S.; Lee, S.H.; Emson, P.C.; Suh, Y.H. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J., 2006, 20 (6), 729-731.
163. Green, K.N.; Billings, L.M.; Roozendaal, B.; McGaugh, J.L.; LaFerla, F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci., 2006, 26 (35), 9047-9056.
164. Catania, C.; Sotiropoulos, I.; Silva, R.; Onofri, C.; Breen, K.C.; Sousa, N.; Almeida, O.F. The amyloidogenic potential and behavioral correlates of stress. Mol. Psychiatry, 2009, 14 (1), 95-105.
165. Sotiropoulos, I.; Catania, C.; Riedemann, T.; Fry, J.P.; Breen, K.C.; Michaelidis, T.M.; Almeida, O.F.X. Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in rat neuronal cells expressing human tau. J. Neurochem., 2008, 107 (2), 385-397.
166. Wakabayashi, K.; Takahashi, H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur. Neurol., 1997, 38 (Suppl 2), 2-7.
167. Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24 (2), 197-211.
168. Braak, H.; Muller, C.M.; Rub, U.; Ackermann, H.; Bratzke, H.; de Vos, R.A.; Del Tredici, K. Pathology associated with sporadic Parkinson's disease--where does it end? J. Neural Transm. Suppl., 2006, 70, 89-97.
169. Kempster, P.A.; O'Sullivan, S.S.; Holton, J.L.; Revesz, T.; Lees, A.J. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain, 2010, 133 (Pt 6), 1755-1762.
170. Hirsch, E.C.; Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol., 2009, 8 (4), 382-397.
171. Halliday, G.; Lees, A.; Stern, M. Milestones in Parkinson's disease--clinical and pathologic features. Mov. Disord., 2011, 26 (6), 1015-1021.
172. Corti, O.; Lesage, S.; Brice, A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev., 2011, 91 (4), 1161-1218.
173. Rabey, J.M.; Scharf, M.; Oberman, Z.; Zohar, M.; Graff, E. Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson's dementia. Biol. Psychiatry, 1990, 27 (6), 581-591.
174. Stypula, G.; Kunert-Radek, J.; Stepien, H.; Zylinska, K.; Pawlikowski, M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation, 1996, 3 (2-3), 131-134.
175. Charlett, A.; Dobbs, R.J.; Purkiss, A.G.; Wright, D.J.; Peterson, D.W.; Weller, C.; Dobbs, S.M. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol. Scand., 1998, 97 (2), 77-85.
176. Ros-Bernal, F.; Hunot, S.; Herrero, M.T.; Parnadeau, S.; Corvol, J.C.; Lu, L.; Alvarez-Fischer, D.; Carrillo-de Sauvage, M.A.; Saurini, F.; Coussieu, C.; Kinugawa, K.; Prigent, A.; Hoglinger, G.; Hamon, M.; Tronche, F.; Hirsch, E.C.; Vyas, S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc. Natl. Acad. Sci. USA, 2011, 108 (16), 6632-6637.
177. Javoy-Agid, F.; Ruberg, M.; Pique, L.; Bertagna, X.; Taquet, H.; Studler, J.M.; Cesselin, F.; Epelbaum, J.; Agid, Y. Biochemistry of the hypothalamus in Parkinson's disease. Neurology, 1984, 34 (5), 672-675.
178. Shannak, K.; Rajput, A.; Rozdilsky, B.; Kish, S.; Gilbert, J.; Hornykiewicz, O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res., 1994, 639 (1), 33-41.
179. Politis, M.; Piccini, P.; Pavese, N.; Koh, S.B.; Brooks, D.J. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp. Neurol., 2008, 214 (1), 112-116.
180. Smith, A.D.; Castro, S.L.; Zigmond, M.J. Stress-induced Parkinson's disease: a working hypothesis. Physiol. Behav., 2002, 77 (4-5), 527-531.
181. Metz, G.A. Stress as a modulator of motor system function and pathology. Rev. Neurosci., 2007, 18 (3-4), 209-222.
182. Snyder, A.M.; Stricker, E.M.; Zigmond, M.J. Stress-induced neurological impairments in an animal model of parkinsonism. Ann. Neurol., 1985, 18 (5), 544-551.
183. Smith, L.K.; Jadavji, N.M.; Colwell, K.L.; Katrina Perehudoff, S.; Metz, G.A. Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. Eur. J. Neurosci., 2008, 27 (8), 2133-2146.
184. Barrot, M.; Abrous, D.N.; Marinelli, M.; Rouge-Pont, F.; Le Moal, M.; Piazza, P.V. Influence of glucocorticoids on dopaminergic transmission in the rat dorsolateral striatum. Eur. J. Neurosci., 2001, 13 (4), 812-818.
185. Gerfen, C.R.; Surmeier, D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci., 2011, 34, 441-466.
186. Day, M.; Wang, Z.; Ding, J.; An, X.; Ingham, C.A.; Shering, A.F.; Wokosin, D.; Ilijic, E.; Sun, Z.; Sampson, A.R.; Mugnaini, E.; Deutch, A.Y.; Sesack, S.R.; Arbuthnott, G.W.; Surmeier, D.J. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci., 2006, 9 (2), 251-259.
187. Serrano-Pozo, A.; Mielke, M.L.; Gomez-Isla, T.; Betensky, R.A.; Growdon, J.H.; Frosch, M.P.; Hyman, B.T. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am. J. Pathol., 2011, 179 (3), 1373-1384.
188. Butovsky, O.; Talpalar, A.E.; Ben-Yaakov, K.; Schwartz, M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell Neurosci., 2005, 29 (3), 381-393.
189. Ouchi, Y.; Yoshikawa, E.; Sekine, Y.; Futatsubashi, M.; Kanno, T.; Ogusu, T.; Torizuka, T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol., 2005, 57 (2), 168-175.
190. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38 (8), 1285-1291.
191. Miklossy, J.; Doudet, D.D.; Schwab, C.; Yu, S.; McGeer, E.G.; McGeer, P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol., 2006, 197 (2), 275-283.
192. McGeer, P.L.; McGeer, E.G. Glial reactions in Parkinson's disease. Mov. Disord., 2008, 23 (4), 474-483.
193. Brochard, V.; Combadiere, B.; Prigent, A.; Laouar, Y.; Perrin, A.; Beray-Berthat, V.; Bonduelle, O.; Alvarez-Fischer, D.; Callebert, J.; Launay, J.M.; Duyckaerts, C.; Flavell, R.A.; Hirsch, E.C.; Hunot, S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest., 2009, 119 (1), 182-192.
194. Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience, 1996, 72 (2), 355-363.
195. Dobbs, R.J.; Charlett, A.; Purkiss, A.G.; Dobbs, S.M.; Weller, C.; Peterson, D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand., 1999, 100 (1), 34-41.
196. Kurkowska-Jastrzebska, I.; Wronska, A.; Kohutnicka, M.; Czlonkowski, A.; Czlonkowska, A. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol., 1999, 156 (1), 50-61.
197. Liberatore, G.T.; Jackson-Lewis, V.; Vukosavic, S.; Mandir, A.S.; Vila, M.; McAuliffe, W.G.; Dawson, V.L.; Dawson, T.M.; Przedborski, S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 1999, 5 (12), 1403-1409.
198. Hunot, S.; Vila, M.; Teismann, P.; Davis, R.J.; Hirsch, E.C.; Przedborski, S.; Rakic, P.; Flavell, R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2004, 101 (2), 665-670.
199. Mount, M.P.; Lira, A.; Grimes, D.; Smith, P.D.; Faucher, S.; Slack, R.; Anisman, H.; Hayley, S.; Park, D.S. Involvement of interferongamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci., 2007, 27 (12), 3328-3337.
200. Landfield, P.W.; Blalock, E.M.; Chen, K.C.; Porter, N.M. A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. Curr. Alzheimer Res., 2007, 4 (2), 205-212.
201. Wang, Y.; Li, M.; Tang, J.; Song, M.; Xu, X.; Xiong, J.; Li, J.; Bai, Y. Glucocorticoids facilitate astrocytic amyloid-beta peptide deposition by increasing the expression of APP and BACE1 and decreasing the expression of amyloid-beta-degrading proteases. Endocrinology, 2011, 152 (7), 2704-2715.
202. Yu, S.; Yang, S.; Holsboer, F.; Sousa, N.; Almeida, O.F. Glucocorticoid regulation of astrocytic fate and function. PLoS One, 2011, 6 (7), e22419.
203. Zschocke, J.; Bayatti, N.; Clement, A.M.; Witan, H.; Figiel, M.; Engele, J.; Behl, C. Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions. J. Biol. Chem., 2005, 280 (41), 34924-34932.
204. Simard, M.; Couldwell, W.T.; Zhang, W.; Song, H.; Liu, S.; Cotrina, M.L.; Goldman, S.; Nedergaard, M. Glucocorticoidspotent modulators of astrocytic calcium signaling. Glia, 1999, 28 (1), 1-12.
205. Sugama, S.; Takenouchi, T.; Kitani, H.; Fujita, M.; Hashimoto, M. Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration. J. Neuroimmunol., 2009, 208 (1-2), 104-114.
206. Morale, M.C.; Serra, P.A.; Delogu, M.R.; Migheli, R.; Rocchitta, G.; Tirolo, C.; Caniglia, S.; Testa, N.; L'Episcopo, F.; Gennuso, F.; Scoto, G.M.; Barden, N.; Miele, E.; Desole, M.S.; Marchetti, B. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J., 2004, 18 (1), 164-166.
207. Clausen, B.E.; Burkhardt, C.; Reith, W.; Renkawitz, R.; Forster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res., 1999, 8 (4), 265-277.
208. Turiault, M.; Parnaudeau, S.; Milet, A.; Parlato, R.; Rouzeau, J.D.; Lazar, M.; Tronche, F. Analysis of dopamine transporter gene expression pattern--generation of DAT-iCre transgenic mice. FEBS J., 2007, 274 (14), 3568-3577.
209. Ghosh, A.; Roy, A.; Liu, X.; Kordower, J.H.; Mufson, E.J.; Hartley, D.M.; Ghosh, S.; Mosley, R.L.; Gendelman, H.E.; Pahan, K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2007, 104 (47), 18754-18759.
210. Chen, L.F.; Greene, W.C. Shaping the nuclear action of NFkappaB. Nat. Rev. Mol. Cell Biol., 2004, 5 (5), 392-3401.
211. Graff, J.; Rei, D.; Guan, J.S.; Wang, W.Y.; Seo, J.; Hennig, K.M.; Nieland, T.J.; Fass, D.M.; Kao, P.F.; Kahn, M.; Su, S.C.; Samiei, A.; Joseph, N.; Haggarty, S.J.; Delalle, I.; Tsai, L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 2012, 483 (7388), 222-226.
212. Sierra, A.; Gottfried-Blackmore, A.; Milner, T.A.; McEwen, B.S.; Bulloch, K. Steroid hormone receptor expression and function in microglia. Glia, 2008, 56 (6), 659-674.
213. Raber, J. Detrimental effects of chronic hypothalamic-pituitaryadrenal axis activation. From obesity to memory deficits. Mol. Neurobiol., 1998, 18 (1), 1-22.
214. Barnes, P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol., 2011, 163 (1), 29-43.
215. Yusim, A.; Ajilore, O.; Bliss, T.; Sapolsky, R. Glucocorticoids exacerbate insult-induced declines in metabolism in selectively vulnerable hippocampal cell fields. Brain Res., 2000, 870 (1-2), 109-117.
216. Abraham, I.; Harkany, T.; Horvath, K.M.; Veenema, A.H.; Penke, B.; Nyakas, C.; Luiten, P.G. Chronic corticosterone administration dose-dependently modulates Abeta (1-42)-and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J. Neuroendocrinol., 2000, 12 (6), 486-494.
217. Crochemore, C.; Lu, J.; Wu, Y.; Liposits, Z.; Sousa, N.; Holsboer, F.; Almeida, O.F.X. Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol. Psychiatry, 2005, 10 (8), 790-798.
218. MacPherson, A.; Dinkel, K.; Sapolsky, R. Glucocorticoids worsen excitotoxin-induced expression of pro-inflammatory cytokines in hippocampal cultures. Exp. Neurol., 2005, 194 (2), 376-383.
219. Munhoz, C.D.; Sorrells, S.F.; Caso, J.R.; Scavone, C.; Sapolsky, R.M. Glucocorticoids exacerbate lipopolysaccharide-induced signaling in the frontal cortex and hippocampus in a dosedependent manner. J. Neurosci., 2010, 30 (41), 13690-13698.
220. Frank, M.G.; Miguel, Z.D.; Watkins, L.R.; Maier, S.F. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav. Immun., 2010, 24 (1), 19-30.
221. Rangon, C.M.; Fortes, S.; Lelievre, V.; Leroux, P.; Plaisant, F.; Joubert, C.; Lanfumey, L.; Cohen-Salmon, C.; Gressens, P. Chronic mild stress during gestation worsens neonatal brain lesions in mice. J. Neurosci., 2007, 27 (28), 7532-7540.
222. Alexander, J.K.; DeVries, A.C.; Kigerl, K.A.; Dahlman, J.M.; Popovich, P.G. Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. Brain Behav. Immun., 2009, 23 (6), 851-860.
223. Jeanneteau, F.; Garabedian, M.J.; Chao, M.V. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc. Natl. Acad. Sci. USA, 2008, 105 (12), 4862-4867.
224. Du, J.; Wang, Y.; Hunter, R.; Wei, Y.; Blumenthal, R.; Falke, C.; Khairova, R.; Zhou, R.; Yuan, P.; Machado-Vieira, R.; McEwen, B.S.; Manji, H.K. Dynamic regulation of mitochondrial function by glucocorticoids. Proc. Natl. Acad. Sci. USA, 2009, 106 (9), 3543-3548.